ClinicalTrials.gg
Not yet recruitingNCT07948668CHCUpdated Nov 19, 2026

Cardiohepatic Cohort: The Heart-Liver Axis Study

An observational study in Metabolic Dysfunction-Associated Steatotic Liver Disease, Major Adverse Cardiovascular Events and Liver Fibrosis, sponsored by First Affiliated Hospital Xi'an Jiaotong University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by First Affiliated Hospital Xi'an Jiaotong University · Observational

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
50,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 216 studies in Liver Cirrhosis with a site in China — 66 open to participants now, 74 under way, 4 of them phase 3. Liver Cirrhosis · China.

Planned enrollment
Largest of 88
50,000 · median 461
Started
2026
with 20 others
Observational
88 of 216
26 open now
Primary completion
2046-08
later than 73 of 73 live
Registered
215th of 216
by date

Among the 216 studies in Liver Cirrhosis with a site in China, this one has the largest planned enrollment of the 88 observational ones that give a count, is one of 21 that started in 2026, is one of 88 observational ones, reaches primary completion later than 73 of the 73 other live ones, and was the 215th registered.

Liver Cirrhosis

1,303 studies on the registry are indexed under Liver Cirrhosis; 340 are open to participants now.

Browse Liver Cirrhosis studies →

Open to participants now

66 of the 216 studies in Liver Cirrhosis with a site in China are open now. Recruiting first, the newest first:

61 more — sign in →

All 66 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 216 studies in Liver Cirrhosis with a site in China, or all of them as a file.
02

Study summary

The goal of this observational study is to investigate the relationship between liver health and cardiovascular diseases in adults. The study aims to understand how liver fat, liver scarring, and other liver changes are related to heart structure, heart function, and cardiovascular events over time.

The main questions it aims to answer are:

  • Are liver imaging features and liver-related blood test results associated with the risk of developing cardiovascular diseases?
  • Are changes in liver health associated with changes in heart structure and function?
  • Are liver-related changes associated with major cardiovascular events, including heart attack, stroke, heart failure hospitalization, and cardiovascular death?

Researchers will study two groups of participants: a retrospective cohort, using existing medical records and imaging data, and a prospective cohort, following participants over time.

Participants in the prospective cohort will have their medical information, laboratory results, and imaging findings collected during routine care. They will also provide blood and other biological samples, with informed consent, for future research. Researchers will follow participants to assess changes in liver health, heart function, and cardiovascular outcomes. No study treatment will be assigned, and participants will continue to receive their usual medical care.

Read the detailed description

The liver and cardiovascular system have complex and bidirectional interactions. The liver plays an important role in glucose and lipid metabolism, inflammation, blood clotting, and the production of circulating proteins and metabolic factors. Abnormal liver metabolism, fat accumulation, and liver fibrosis may be associated with the development and progression of cardiovascular diseases. Conversely, cardiovascular dysfunction, particularly heart failure and elevated venous pressure, may contribute to liver injury and fibrosis.

However, the longitudinal relationships between liver abnormalities, cardiac structural and functional changes, and long-term cardiovascular outcomes remain incompletely understood. In particular, large-scale studies integrating liver imaging, cardiac imaging, clinical laboratory results, longitudinal follow-up, and biological samples are limited.

The Cardiohepatic Cohort (CHC) is a multicenter, observational, ambispective, real-world cohort study led by the First Affiliated Hospital of Xi'an Jiaotong University. The study aims to establish an integrated research platform to investigate the bidirectional relationship between liver health and cardiovascular diseases.

The study consists of two cohorts:

  1. **Retrospective Cohort:** Eligible participants who previously received medical care at participating centers will be identified through electronic medical records, laboratory databases, medical imaging systems, and follow-up databases. Researchers will collect existing clinical information, liver-related laboratory results, abdominal imaging findings, cardiovascular risk factors, cardiac imaging data, treatment information, and clinical outcomes. The planned retrospective cohort will include at least 10,000 participants.
  2. **Prospective Cohort:** Eligible participants will be consecutively enrolled at participating centers. Researchers will establish a standardized electronic case report form (eCRF) to collect baseline clinical information and follow participants longitudinally. With informed consent, blood and other biological samples will be collected and stored in a biobank for future biomarker and mechanistic studies.

**Study Population and Data Collection**

The study will include adults aged 18 years or older with relevant clinical information. The prospective cohort will include participants with cardiovascular diseases, metabolic disorders, and individuals undergoing abdominal imaging examinations.

Data collected will include:

  • Demographic characteristics and cardiovascular risk factors, including age, sex, body mass index, smoking, alcohol consumption, hypertension, diabetes, dyslipidemia, and chronic kidney disease.
  • Liver-related laboratory measurements, including alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transferase, bilirubin, albumin, platelet count, and other relevant metabolic and liver fibrosis-related indicators.
  • Abdominal imaging findings from ultrasound, computed tomography (CT), and magnetic resonance imaging (MRI), including liver fat accumulation, liver density, liver volume, and imaging features associated with fibrosis.
  • Cardiovascular assessments, including electrocardiography, ambulatory electrocardiographic monitoring, echocardiography, cardiac CT, and cardiac MRI, when available.
  • Cardiovascular diagnoses, treatment information, disease progression, hospitalizations, and mortality outcomes.

**Follow-up and Clinical Outcomes**

Participants in the prospective cohort will undergo follow-up according to the study schedule, including assessments at 3, 6, 12, 24, 36, 48, and 60 months after enrollment. Follow-up will include clinical status, treatment changes, laboratory results, electrocardiographic findings, cardiac imaging, liver-related assessments, and cardiovascular events. Follow-up information will be obtained through outpatient visits, hospital records, telephone interviews, and electronic medical records.

The primary research focus is the longitudinal association between liver-related phenotypes and cardiovascular outcomes. Major adverse cardiovascular events (MACE) will include cardiovascular death, myocardial infarction, ischemic stroke, and hospitalization for heart failure.

Other important cardiovascular outcomes will include incident atrial fibrillation, new-onset heart failure, coronary artery disease events, and malignant ventricular arrhythmias.

Secondary assessments will include changes in cardiac structure and function, such as left atrial volume index, left ventricular ejection fraction, diastolic function, and ventricular remodeling parameters. Electrocardiographic outcomes will include atrial fibrillation burden, premature ventricular contractions, complex arrhythmias, and heart rate variability. Changes in liver imaging phenotypes, cardiac imaging findings, rehospitalization, and all-cause mortality will also be evaluated.

**Biological Sample Collection and Exploratory Mechanistic Studies**

In the prospective cohort, biological samples will be collected with informed consent according to the study protocol. These may include peripheral blood, urine, and stool samples. Additional tissue or body fluid samples, such as liver tissue, myocardial tissue, thrombi, and pericardial fluid, may be collected when available from clinically indicated procedures or routine medical care. The study will not require additional invasive procedures solely for research sample collection.

Selected samples and representative participant subgroups will be used for exploratory analyses, including proteomics, metabolomics, inflammatory biomarker measurements, and other molecular studies. These investigations aim to identify potential biological pathways linking liver abnormalities with cardiovascular injury and remodeling.

**Overall Study Objectives**

The Cardiohepatic Cohort aims to:

  1. Evaluate the longitudinal associations between liver imaging phenotypes, liver-related metabolic indicators, and cardiovascular diseases.
  2. Characterize the relationships between liver abnormalities and changes in cardiac structure, function, and electrical activity.
  3. Assess the associations between dynamic changes in liver health and long-term cardiovascular outcomes.
  4. Explore potential metabolic, inflammatory, and molecular pathways underlying the bidirectional liver-heart relationship using biological samples and multi-omics approaches.

This is an observational study. No investigational treatment or intervention will be assigned. Participants will continue to receive medical care according to their treating physicians' decisions. The study will provide a comprehensive real-world research platform for understanding the liver-heart axis and supporting future cardiovascular risk assessment and precision medicine.

03

Conditions studied

  • Metabolic Dysfunction-Associated Steatotic Liver Disease
  • Major Adverse Cardiovascular Events
  • Liver Fibrosis

Keywords

  • Cardiohepatic axis
  • Liver imaging
  • Hepatic steatosis
  • Cardiovascular remodeling
  • Multimodal data
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults aged 18 years or older receiving medical care at the First Affiliated Hospital of Xi'an Jiaotong University and participating centers will be included. The retrospective cohort will identify eligible participants from existing electronic medical records, laboratory databases, imaging systems, and follow-up records, requiring at least one abdominal imaging examination or documented liver-related assessment. The prospective cohort will consecutively enroll eligible adults with cardiovascular diseases, metabolic abnormalities, or those undergoing abdominal imaging, with standardized longitudinal follow-up. Participants will receive routine clinical care without study-assigned interventions. Biospecimen collection and exploratory molecular analyses will be optional and subject to appropriate informed consent or ethical approval. Lack of biospecimens will not exclude participants from the clinical cohort.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Adults aged 18 years or older. Receiving medical care at the participating centers, with available clinical information relevant to liver and cardiovascular assessments, including demographic characteristics, clinical diagnoses, and laboratory data.

For the retrospective cohort: at least one abdominal imaging examination or documented liver-related assessment during the relevant observation period.

For the prospective cohort: individuals receiving care for cardiovascular diseases, metabolic abnormalities, or undergoing abdominal imaging examinations, who are able to complete standardized longitudinal follow-up.

For the prospective cohort: willingness and ability to participate in the study and provide written .

Exclusion criteria

Exclusion Criteria:

Advanced or an expected survival time of less than 6 months. Severe active infection, acute inflammatory conditions, or other conditions at enrollment that may substantially interfere with the assessment of the principal study measures.

Active viral hepatitis, severe liver disease, or other specific liver diseases that may substantially confound the evaluation of liver-related metabolic phenotypes.

For the retrospective cohort: insufficient key clinical information to establish eligibility or ascertain the primary study outcomes.

For the prospective cohort: inability or unwillingness to participate in standardized longitudinal follow-up or refusal to provide written .

Note: Participation in biospecimen collection and exploratory molecular analyses is optional and is not a requirement for enrollment in the overall clinical cohort. Refusal or inability to provide biological samples will not affect eligibility for the clinical cohort or participation in clinical follow-up.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
50,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Retrospective Cohort

    This cohort includes eligible adults aged 18 years or older who previously received medical care at participating centers. Existing electronic medical records, laboratory results, abdominal and cardiac imaging data, treatment information, and follow-up records will be retrospectively collected and analyzed. Liver-related phenotypes, cardiovascular risk factors, cardiac structure and function, and long-term cardiovascular outcomes will be evaluated. Previously collected biological samples may be used when available and ethically approved. No additional clinical procedures or interventions will be performed.

  • Prospective Cohort

    This cohort includes eligible adults aged 18 years or older who will be consecutively enrolled at participating centers. Baseline clinical characteristics, liver-related laboratory measurements, abdominal imaging findings, cardiac assessments, and treatment information will be collected. Participants will undergo longitudinal follow-up to assess changes in liver health, cardiac structure and function, and cardiovascular outcomes. With informed consent, blood and other biological samples will be collected and stored for future biomarker, multi-omics, and exploratory mechanistic analyses. No investigational treatment will be assigned, and routine clinical care will remain unchanged.

06

What researchers measure

Primary outcomes

  1. Time to First Major Adverse Cardiovascular Event (MACE)

    Time from baseline to the first occurrence of a major adverse cardiovascular event (MACE), defined as a composite of cardiovascular death, myocardial infarction, ischemic stroke, or hospitalization for heart failure. The primary measure is the time to the first qualifying event, expressed in days. Only the first qualifying event will be counted. Events will be identified through medical records and follow-up information.

    Time frame: From baseline to the first qualifying event, assessed for up to 60 months.

Secondary outcomes

  1. Number of Participants With New-Onset Heart Failure

    Number of participants without heart failure at baseline who develop clinically documented heart failure during follow-up. Heart failure will be identified through documented clinical diagnoses and supporting medical records, including available cardiac imaging and laboratory findings. The measure will be the number of participants experiencing at least one qualifying event.

    Time frame: From baseline to the first documented diagnosis of heart failure, assessed for up to 60 months.

  2. Number of Participants With New-Onset Atrial Fibrillation

    Number of participants without documented atrial fibrillation at baseline who develop atrial fibrillation during follow-up. Atrial fibrillation will be confirmed by electrocardiography, ambulatory electrocardiographic monitoring, or documented clinical diagnosis supported by available electrocardiographic records. The measure will be the number of participants with at least one confirmed event.

    Time frame: From baseline to the first documented diagnosis of atrial fibrillation, assessed for up to 60 months.

  3. Number of Participants With Malignant Ventricular Arrhythmia Events

    Number of participants experiencing at least one clinically documented malignant ventricular arrhythmia event during follow-up, including sustained ventricular tachycardia, ventricular fibrillation, or cardiac arrest attributable to ventricular arrhythmia. Events will be identified through electrocardiographic documentation, medical records, cardiac monitoring, and available implanted device records.

    Time frame: From baseline to the first qualifying event, assessed for up to 60 months.

  4. Number of Participants With Coronary Artery Disease Events

    Number of participants experiencing at least one clinically documented coronary artery disease event during follow-up. Events are defined as myocardial infarction or hospitalization for unstable angina. Event ascertainment will be based on clinical diagnoses, hospitalization records, and available diagnostic findings.

    Time frame: From baseline to the first qualifying coronary artery disease event, assessed for up to 60 months.

  5. Number of Participants With Unplanned All-Cause Hospital Readmission

    Number of participants experiencing at least one unplanned hospital readmission for any cause following discharge from the index hospitalization. Readmission will be identified through hospital records and follow-up information. Planned admissions and scheduled procedures will be excluded. This measure will be assessed only among participants with an identifiable index hospitalization and discharge date.

    Time frame: From discharge after the index hospitalization to the first unplanned readmission, assessed for up to 60 months.

  6. Time to All-Cause Death (Days)

    Time from baseline to death from any cause, expressed in days. Vital status and date of death will be determined using available medical records and follow-up information.

    Time frame: From baseline to death or the end of follow-up, assessed for up to 60 months.

  7. Change From Baseline in Left Atrial Volume Index (mL/m²)

    Change from baseline in left atrial volume index (LAVI), measured by transthoracic echocardiography and expressed in mL/m². LAVI will be calculated by indexing left atrial volume to body surface area. The change will be calculated as the follow-up value minus the baseline value among participants with available measurements.

    Time frame: Baseline and follow-up assessments at months 3, 6, 12, 24, 36, 48, and 60, when available.

  8. Change From Baseline in Left Ventricular Ejection Fraction (Percentage Points)

    Change from baseline in left ventricular ejection fraction (LVEF), measured by transthoracic echocardiography and expressed in percentage points. LVEF will be determined using available echocardiographic measurements. The change will be calculated as the follow-up value minus the baseline value among participants with available measurements.

    Time frame: Baseline and follow-up assessments at months 3, 6, 12, 24, 36, 48, and 60, when available.

  9. Number of Participants With a Change in Imaging-Defined Hepatic Steatosis Status

    Number of participants with a change in hepatic steatosis status between baseline and follow-up imaging. Hepatic steatosis will be assessed using available abdominal ultrasound, computed tomography, or magnetic resonance imaging according to standardized imaging criteria. Status changes will be classified as new-onset, resolved, persistent, or absent. Longitudinal comparisons will prioritize the same imaging modality, and quantitative measurements from different modalities will not be directly combined.

    Time frame: Baseline and available follow-up imaging assessments through 60 months.

  10. Change From Baseline in Fibrosis-4 Index (FIB-4 Score)

    Change from baseline in the Fibrosis-4 Index (FIB-4), a unitless noninvasive score calculated using age, aspartate aminotransferase, alanine aminotransferase, and platelet count. FIB-4 estimates the risk of advanced liver fibrosis. The change will be calculated as the follow-up score minus the baseline score. Results will be interpreted as changes in estimated fibrosis-related risk rather than direct evidence of histological fibrosis progression or regression.

    Time frame: Baseline and available follow-up laboratory assessments through 60 months.

  11. Change From Baseline in Serum Alanine Aminotransferase (ALT, U/L)

    Change from baseline in serum alanine aminotransferase (ALT) concentration, measured using routine clinical laboratory assays and expressed in U/L. The change will be calculated as the follow-up ALT concentration minus the baseline concentration among participants with available measurements.

    Time frame: Baseline and available follow-up laboratory assessments at months 3, 6, 12, 24, 36, 48, and 60, when available.

Other outcomes

  1. Relative Abundance of Circulating Proteins Measured by Mass Spectrometry (Log2-Transformed Intensity)

    Relative abundance of circulating proteins in available stored blood samples, measured using mass spectrometry-based proteomic analysis (LC-MS/MS). Protein abundance will be expressed as normalized, log2-transformed protein intensity in arbitrary units. The same normalized intensity scale will be used for each protein analyzed. Exploratory analyses will investigate associations between circulating protein abundance, liver-related phenotypes, cardiac structural and functional changes, and cardiovascular outcomes. Analyses will be conducted in selected participants with available biospecimens and appropriate informed consent or ethical approval.

    Time frame: Baseline and available follow-up biospecimen assessments through 60 months.

  2. Relative Abundance of Circulating Metabolites Measured by Mass Spectrometry (Log2-Transformed Intensity)

    Relative abundance of circulating metabolites in available stored blood samples, measured using mass spectrometry-based metabolomic analysis (LC-MS/MS). Metabolite abundance will be expressed as normalized, log2-transformed peak intensity in arbitrary units. The same normalized intensity scale will be used for each metabolite analyzed. Exploratory analyses will investigate associations between circulating metabolite abundance, liver-related phenotypes, cardiac structural and functional changes, and cardiovascular outcomes. Analyses will be conducted in selected participants with available biospecimens and appropriate informed consent or ethical approval.

    Time frame: Baseline and available follow-up biospecimen assessments through 60 months.

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Aug 2046, 236 months later.

Of 231 non-industry observational studies under Liver Cirrhosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 71. This study's planned 236 months is above that.

Counting every sponsor, half of 247 studies reached it within 47 months; a quarter within 18 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2026
First posted
Nov 19, 2026
StartEst.
Nov 11, 2026
Primary completionEst.
Aug 1, 2046
CompletionEst.
Aug 1, 2046
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07948668
Responsible party
Sponsor
First posted
Nov 19, 2026
Start date
Nov 11, 2026 (estimated)
Primary completion
Aug 1, 2046 (estimated)
Completion
Aug 1, 2046 (estimated)
Last update
Nov 19, 2026

Study contacts

Guoliang Li
Contact
guoliangli@xjtu.edu.cn
0086-2985323868
Yang Yan
Contact
yangyan3@xjtu.edu.cn
0086-2985323865
Guoliang Li
principal investigator · First Affiliated Hospital Xi'an Jiaotong University
Yang Yan
principal investigator · First Affiliated Hospital Xi'an Jiaotong University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion